By Dr. Peter Vanderklish Many neurological disorders appear very different clinically, yet an important biological theme is emerging across them: early loss of synaptic connectivity. In a recent article published in The Scientist, Dr. Vanderklish, Chief Science Officer at Spinogenix, examines synapse loss as a point of convergence across conditions including Alzheimer’s disease, amyotrophic lateral…
When Stead Impact Ventures Board Chair Jerre Stead sat down with Dr. Stella Sarraf, founder and CEO of Spinogenix, their discussion centered on one shared belief: patients deserve more than incremental progress. They deserve treatments that can truly change their lives. For Stella, that mission is deeply personal. As a daughter and caregiver, she’s seen…
Posted in Life Science Podcast By: Ayesha Rashid, PhD In this episode of the Xtalks Life Science Podcast, Ayesha speaks with Stella Sarraf, PhD, CEO and Founder of Spinogenix, a company pioneering novel neurodegenerative therapeutics designed to restore synapses with the potential to reverse cognitive and motor decline in conditions such as ALS, Alzheimer’s disease,…
We’re thrilled to share that our CEO and Founder, Stella Sarraf, PhD, has been named to Forbes 2025 Class of 50 Over 50: Innovation list. This recognition celebrates trailblazers who are redefining what’s possible in science, technology, and business—and we couldn’t be prouder to see Stella honored for her bold vision and unwavering commitment to…
Spinogenix has reached a major milestone in its mission to transform neuropsychiatric care. Following FDA clearance of an IND application, enrollment is now open at a U.S. site for a Phase 2 clinical trial of SPG302—the first synaptic regenerative therapy being developed for schizophrenia. In a recent interview, Christoph U. Correll, MD, shared why this…
October marks the annual occurrence of several international events aimed at expanding awareness of mental health disorders, including schizophrenia. In this blog post, Spinogenix Chief Science Officer Dr. Peter Vanderklish and Chief Medical Advisor Dr. Craig Erickson provide insights into how synaptic regeneration with SPG302 may provide a new and potentially transformative therapeutic approach in…
Drug development is a complicated, expensive, and time-consuming activity that requires thoughtful application of scientific and medical principles to bring the best possible treatments forward to affected patients. In general terms, to improve our ability to quickly advance potential treatments through the early phases of clinical evaluation, we need to improve how we measure drug…